In the News

People with Down syndrome helped scientists pave the way for Alzheimer’s drugs but are now left out of the treatment. By Hampus Hillerstrom and Jo Ann Simons  The clinical trials for new Alzheimer’s disease treatment drugs — which researchers believe will slow the course of the disease over time — offer hope to thousands of […]

By Sydney RoellSARASOTA COUNTY,  Fla. (SNN) — In honor of Sept. 21 being World Alzheimer’s Day, a group of Sarasota researchers hosted a free bilingual memory screening. Intercoastal Medical Group Neurology and Research Clinic offered their free, confidential memory screening in English and Spanish on Thursday from 8 a.m. to 3 p.m. at Robert L. Taylor […]

By Janet Lee – Washington Post Consumer Reports has no financial relationship with any advertisers on this site. Doing puzzles, playing memory-boosting games, taking classes and reading are activities that we often turn to for help keeping our brains sharp. But research is showing that what you eat, how often you exercise and the type of exercise you do […]

Free, bilingual screening on World Alzheimer’s Day Intercoastal Medical Group Neurology and Research Clinic will hold a free, bilingual?memory?screening event on World Alzheimer’s Day on Sept. 21 from 8 a.m. to 3 p.m. at Robert L. Taylor Community Complex, 1845 John Rivers St., in Sarasota. The goal of the confidential? screening in English and Spanish […]

Jessica Cantu from GAP-Net site El Faro Health and Therapeutics was at the Alzheimer’s Association’s International Conference (AAIC) in Amsterdam and spoke about the creation of the site in Starr County, Texas. En el condado Starr, casi uno en cada cuatro adultos de 65 años de edad en adelante fueron diagnosticados con Alzheimer en el […]

By Cathy Kelly Medicare policymakers have felt that without an effective approved treatment, coverage of amyloid PET scans and APOE4 genetic tests was not warranted. But that is changing. There is more to Medicare coverage for Alzheimer’s treatment than Leqembi, Eisai Co., Ltd. and Biogen, Inc.’s newly-approved amyloid-targeting monoclonal antibody. Now the program also is considering amending restrictive coverage […]

By Cathy Kelly There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years. The Centers for Medicare and Medicaid Services is sticking with its plan to provide broader Medicare coverage for Eisai Co., Ltd. and Biogen, Inc.’s Leqembi for Alzheimer’s – now that […]

GAP Community Connector, Paula Atkinson, was a guest writer for the Orlando Times and explained why she and GAP are committed to advancing Alzheimer’s clinical research in Black and Brown communities. My grandmother was treated for Alzheimer’s disease, but never diagnosed with it. Why? She was toldby her doctor that it would take too long […]

GAP-Net Site Kerwin Medical Center was featured in Community Impact on the rate of Alzheimer’s disease in Hispanic communities, and how they can help. As part of a nationwide study, Kerwin Medical Center is testing the efficacy of Aducanumab, a drug that helps a type of plaque in the brain and slows memory impairment caused […]

GAP-Net Site K2 Medical Research was featured in the Orlando Times speaking about the rate of Alzheimer’s in the black community, and studies they have that can help. ORLANDO – For the 580,000 Floridians who are living with Alzheimer’s disease, or for the state’s 1.1 million citizens who who serve as unpaid Alzheimer’s caregivers, one […]

GAP President John Dwyer was quoted in the Financial Times talking about how the CMS decision will limit patient access to possible life saving Alzheimer’s treatments. Eisai has warned that mandatory data collection by US health authorities could restrictpatient access to the Japanese drugmaker’s new Alzheimer’s treatment. The company said a decision by Centers for […]

GAP President John Dwyer was featured in McKnights Senior Living on the CMS decision to support only traditionally FDA-approved drugs. A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in the details.” CMS […]

GAP President John Dwyer was quoted in the Washington Post on the CMS decision. The Centers for Medicare and Medicaid Services said it would cover a class of Alzheimer’s drugs that includes Leqembi if the medicines get traditional approval by drug regulators. (Eisai/Reuters) Medicare officials outlined plans Thursday to broadly cover a new class of […]

GAP-Net Site The Alzheimer’s Disease Research Center of Albany is looking for volunteers for their research studies. ALBANY — The Alzheimer’s Disease  Research Center of Albany is looking for volunteers for an Alzheimer’s clinical study, putting an emphasis on the recruitment of people of color.  While people from underrepresented communities — including those who are […]

WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors […]

House Energy & Commerce Subcommittee Tells CMS: Fix Alzheimer’s Drug Coverage WASHINGTON, DC (April 27, 2023) – The Global Alzheimer’s Platform Foundation®(GAP) President John Dwyer commends the strong, bipartisan leadership shown yesterday by U.S. Reps. Brett Guthrie (R-KY) and Anna Eshoo (D-CA) for admonishing the U.S. Centers for Medicare and Medicaid Services (CMS) administrator Chiquita […]

2022 Citizen Scientist Champion Award Elevated Honoree, Bob Deady, was featured in the KU ADRC publication for his dedication to Alzheimer’s research. There’s a familiar face around the University of Kansas Alzheimer’s Disease Research Center (KU ARDC). He doesn’t have an office, or a nameplate on the door or letters behind his name. But he’s doing his […]

GAP President John Dwyer wrote an op-ed in the Dallas Examiner calling on President Biden to reverse the Centers for Medicare and Medicaid Services to cover Leqembi and future Alzheimer’s drugs and treatments. The Biden administration has a big problem on its hands. It’s sending mixed signals on new Food and Drug Administration approved Alzheimer’s […]

by Barbara Campos – Telemundo According to the conclusions of a new Alzheimer’s Association report, Hispanics are almost twice as at risk as other demographic groups, and caring for patients can place a heavy burden on households. The report illustrates the need to allocate more resources and efforts to raise awareness about a degenerative disease […]

BAY VILLAGE, Ohio — There are two newly-approved treatments to treat Alzheimer’s Disease, but getting them covered by medicare is a battle. Alzheimer’s impacts nearly 6 million Americans over the age of 65, and that number is expected to triple by 2060. It is the sixth leading cause of death in the U.S., according to […]

GAP Associate Director of Recruitment & Strategic Initiatives, Dr. Tamiko MaGee Rodgers, was featured on the Roland Martin Unfiltered Daily Digital Show and spoke about Alzheimer’s disease clinical trials.

GAP President John Dwyer spoke with Cathy Kelly of Pink Sheet about the Bio-Hermes study, the necessity for diversity in #Alzheimers clinical trials, and how industry-sponsored trials are out pacing government-sponsored trials.  Although Alzheimer’s stakeholders are dismayed by the treatment access restrictions imposed by the Medicare national coverage determination last spring, the policy has also jumpstarted […]

GAP President, John Dwyer, spoke to Genome Web about the closing of our Bio-Hermes study, and what the results may do for the future of Alzheimer’s research. The Global Alzheimer’s Platform (GAP) has completed a first-of-its-kind cross sectional study comparing the performance of Alzheimer’s diagnostic assays. Topline results are expected in July of next year, […]